Becenun - General Information
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Pharmacology of Becenun
Becenun is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Becenun for patients
No information provided.
BiCNU should not be given to individuals who have demonstrated a previous hypersensitivity to it.
Additional information about Becenun
Becenun Indication: For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Mechanism Of Action: Becenun causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Becenun also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Carmustine
Synonyms: BCNU; Bischlorethylnitrosourea; Bischlorethylnitrosurea; Carmustin
Drug Category: Antineoplastic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Carmustine: Becenun; Bi CNU; Carmubris; Gliadel; Gliadel Wafer; Nitrumon; BiCNU;
Absorption: 5 to 28% bioavailability
Toxicity (Overdose): The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Protein Binding: 80%
Biotransformation: Hepatic and rapid with active metabolites. Metabolites may persist in the plasma for several days.
Half Life: 15-30 minutes
Dosage Forms of Becenun: Powder, for solution Intravenous
Chemical IUPAC Name: 1,3-bis(2-chloroethyl)-1-nitrosourea
Chemical Formula: C5H9Cl2N3O2
Carmustine on Wikipedia: http://en.wikipedia.org/wiki/Carmustine
Organisms Affected: Humans and other mammals